SciSparc to Acquire Controlling Interest in Miza III Ventures, Transferring Pharmaceutical Portfolio in $11.6M Deal
SciSparc Ltd. has entered into a definitive agreement to acquire a controlling interest in Miza III Ventures Inc., a company listed on the TSX Venture Exchange. As part of the transaction, SciSparc will transfer its advanced clinical stage pharmaceutical portfolio and its approximately 51% equity stake in SciSparc Nutraceuticals Inc. to Miza. These assets are valued at about US$11.6 million. Upon closing, SciSparc will receive 4,000,000 common share purchase warrants from Miza, each exercisable at CAD 0.25 per share for five years. Additionally, SciSparc or a third party plans to provide up to CAD 1,000,000 in capital to Miza through an unsecured convertible note with a 7% annual interest rate, convertible into up to 4,000,000 common shares of Miza. The transaction is expected to close on or around October 22, 2025, subject to satisfaction of closing conditions and regulatory approval.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scisparc Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9545922-en) on October 15, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.